Castle Biosciences (CSTL) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Castle Biosciences (NASDAQ: CSTL):

• 11/1/2026 – Castle Biosciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/29/2026 – Castle Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/29/2026 – Castle Biosciences is now covered by Mizuho. They set an “outperform” rating and a $60.00 price target on the stock.
• 10/24/2026 – Castle Biosciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/26/2026 – Castle Biosciences was upgraded by Wall Street Zen from “hold” to “buy”.

Castle Biosciences Stock Down 6.0%

Shares of NASDAQ:CSTL opened at $34.94 on Tuesday. The stock’s 50-day moving average price is $34.23 and its two-hundred day moving average price is $28.65. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -52.94 and a beta of 0.94.

Insider Transactions at Castle Biosciences

In related news, COO Kristen M. Oelschlager sold 12,384 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $34.42, for a total transaction of $426,257.28. Following the completion of the transaction, the chief operating officer owned 72,649 shares of the company’s stock, valued at approximately $2,500,578.58. This represents a 14.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Derek Maetzold sold 12,428 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $33.20, for a total transaction of $412,609.60. Following the transaction, the insider directly owned 21,479 shares of the company’s stock, valued at $713,102.80. This trade represents a 36.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 129,759 shares of company stock worth $4,434,187 in the last three months. Company insiders own 6.10% of the company’s stock.

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.